Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kevin Grogan

Managing Editor, Europe

Manchester, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest From Kevin Grogan

Sanofi Cements Artificial Intelligence Ambitions With OpenAI and Formation Pact

The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.

Artificial Intelligence Deals

Novavax Sanofi Pact Pacifies Unhappy Investor For Now

The US vaccines maker has been under the cosh from a very vocal investor who was unhappy with the performance of commercially disappointing COVID-19 shot Nuvaxovid and strategy in general. However, a recent pact with Sanofi worth up to $1.2bn has had a soothing effect.

Vaccines Business Strategies

AstraZeneca Confident Of Cementing Lead In Respiratory

The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”

Respiratory Clinical Trials

Bayer Revels In Its Football Club's Remarkable Run

The German group has spent much of the year reviewing the pros and cons of its hybrid structure but there was never any question about divesting Bayer 04 Leverkusen, its extremely successful football team, CEO Bill Anderson told journalists.

Leadership Companies

Bayer Talks Up Eylea Expansion Plans As Patent Expiry Hits

CEO Bill Anderson tells Scrip that the switching of patients to the higher dose formulation of the eye disease drug will help secure its future as a big earner for Bayer.

Sales & Earnings Business Strategies

Almirall Upbeat Over Initial Sales Of Atopic Dermatitis Drug

Ebglyss sales, all from Germany, were €3.6m in the first quarter and while that may appear a little underwhelming at first glance, the Spanish drugmaker is impressed with the launch and its impact on dermatologists and patients.

Sales & Earnings Business Strategies
See All
UsernamePublicRestriction

Register